News Laboratorios Farmaceuticos Rovi, S.A. OTC Markets

Stocks

LABFF

ES0157261019

Pharmaceuticals

Real-time OTC Markets 10:45:10 2023-10-20 am EDT			5-day change	1st Jan Change
52.00 ^USD	-3.93%		-22.58%	-21.05%

Jul. 23	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
Jul. 23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI

All News

Mentions Relevance

Jul. 23	Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
Jul. 23	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
Jul. 23	Laboratorios Farmaceuticos Rovi, S.A. Maintains Earnings Guidance for 2026	CI
Jul. 23	Laboratorios Farmaceuticos Rovi S A : First half 2026 results press release	PU
Jul. 08	Laboratorios Farmaceuticos Rovi S A : ROVI and the Regional Government of Castilla-La Mancha promote a framework of collaboration to modernise healthcare services through technological innovation	PU
May. 09	Laboratorios Farmaceuticos Rovi, S.A., Q1 2026 Earnings Call, May 06, 2026
May. 06	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 06	Laboratorios Farmaceuticos Rovi, S.A. Updates Earnings Guidance for the Full Year 2026	CI
May. 06	Rovi Q1 net profit at 9.4 mln euros	RE
May. 06	Rovi expects risperidone to reach potential sales of 100-200 mln euros globally over next few years	RE
May. 06	Laboratorios Farmaceuticos Rovi S A : First three months of 2026 results press release	PU
Apr. 01	Rovi closes deal to buy pharmaceutical manufacturing facility in US	RE
Feb. 25	Laboratorios Farmaceuticos Rovi, S.A., 2025 Earnings Call, Feb 25, 2026
Feb. 25	Pharmaceutical Company Rovi Increases Net Profit Thanks to Okedi and Heparin Sales	RE
Feb. 25	Drugmaker Rovi's net profit rises on higher Okedi, heparin sales	RE
Feb. 25	Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 25	Laboratorios Farmaceuticos Rovi, S.A. Provides Earnings Guidance for the Fiscal Year 2026	CI
Feb. 25	ROVI Proposes Dividend Distribution for the Year 2025	CI
Feb. 25	Laboratorios Farmaceuticos Rovi S A : 2025 results press release	PU
Feb. 25	Rovi to propose dividend of 0.9594 eur/shr	RE
Feb. 25	Rovi FY Ebitda 216.2 mln euros	RE
Feb. 25	Rovi FY net profit at 140.4 mln euros	RE
Nov. 18	Rovi and Roche sign final agreement for manufacture of new medicine	RE
Nov. 18	Laboratorios Farmaceuticos Rovi S A : ROVI releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development	PU
Nov. 06	Rovi sees 2026 operating revenue to increase by up to low double-digit percentage vs 2025	RE